A61K 48/005
Medicinal preparations containing genetic material which is inserted into cells of the
Official title: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
A61K48/005 (Medicinal preparations containing genetic material which is inserted into cells of the) appears on 3,146 US grants and 8,473 published applications in this corpus.
Search patents in A61K- Granted patents
- 3,146
- Published applications
- 8,473
- Assignees
- 2,273
- Inventors
- 12,562
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 5 | 0 |
| 1999 | 4 | 0 |
| 2000 | 7 | 0 |
| 2001 | 5 | 2 |
| 2002 | 10 | 41 |
| 2003 | 17 | 84 |
| 2004 | 16 | 97 |
| 2005 | 18 | 108 |
| 2006 | 31 | 124 |
| 2007 | 34 | 111 |
| 2008 | 22 | 100 |
| 2009 | 40 | 128 |
| 2010 | 40 | 106 |
| 2011 | 54 | 141 |
| 2012 | 57 | 120 |
| 2013 | 58 | 177 |
| 2014 | 101 | 217 |
| 2015 | 119 | 220 |
| 2016 | 148 | 313 |
| 2017 | 141 | 303 |
| 2018 | 166 | 466 |
| 2019 | 212 | 493 |
| 2020 | 222 | 504 |
| 2021 | 251 | 565 |
| 2022 | 228 | 706 |
| 2023 | 264 | 729 |
| 2024 | 282 | 914 |
| 2025 | 328 | 949 |
| 2026 | 266 | 755 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Methods of preparation of pan TLR antagonistic liposomal-LNP formulations and uses thereof6 Oct 2026US 12,751,920 B2Celestial Therapeutics, Inc.
- Methods and materials for ameliorating creatine deficiency disorders6 Oct 2026US 12,751,995 B2The Regents of the University of California
- Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene6 Oct 2026US 12,752,019 B2Precision BioSciences, Inc.
- Microdystrophin nucleic acid gene therapy constructs and uses thereof6 Oct 2026US 12,752,020 B2REGENXBIO Inc.
- Methods of manufacturing microdystrophin gene therapy constructs6 Oct 2026US 12,752,021 B2REGENXBIO Inc.
- Methods and materials for treating cancer8 Oct 2026US 2026/0306630 A1Mayo Foundation for Medical Education and Research
- Capsids and methods of targeting neurons8 Oct 2026US 2026/0306661 A1Capsigen Inc.
- Formulations comprising recombinant aav and methods of administering the same8 Oct 2026US 2026/0306663 A1Ultragenyx Pharmaceutical Inc.
- Prophylactic steroid regimen for recombinant adeno-associated viral vector therapies8 Oct 2026US 2026/0306664 A1AbbVie Inc.
- Recombinant adeno-associated viral vectors for multipartite gene delivery and stargardt disease treatment8 Oct 2026US 2026/0306667 A1Abeona Therapeutics Inc.
Most cited
By later US patents
- Regulation of endogenous gene expression in cells using zinc finger proteins648US 6,534,261 B1Sangamo BioSciences, Inc. · 2003
- Engineering of systems, methods and optimized guide compositions for sequence manipulation480US 8,906,616 B2Massachusetts Institute of Technology · 2014
- Regulation of endogenous gene expression in cells using zinc finger proteins395US 6,824,978 B1Sangamo BioSciences, Inc. · 2004
- Modulation of endogenous gene expression in cells383US 6,933,113 B2Sangamo BioSciences, Inc. · 2005
- Engineered nucleic acids and methods of use thereof372US 8,822,663 B2Moderna Therapeutics, Inc. · 2014